Wugen, Inc.

Quick facts

Phase 2 pipeline

• WU-CART-007

Phase 1 pipeline

• Cetuximab - Cohort Expansion
• Cetuximab - Dose Escalation
• WU-NK-101
• WU-NK-101 - Cohort Expansion
• WU-NK-101 - Dose Escalation

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Wugen, Inc. portfolio CI brief
• Wugen, Inc. pipeline updates RSS

Related

• Sector hub: All tracked pharma companies